TREATMENT OF METABOLICALLY ASSOCIATED FATTY LIVER DISEASE IN THE YOUNG POPULATION

dc.contributor.author	Tursunova Nozima Sultanovna
dc.contributor.author	Scientific Supervisor: Atakhodjaeva G. A.
dc.date.accessioned	2025-12-29T11:30:36Z
dc.date.issued	2024-09-19
dc.description.abstract	Metabolically Associated Fatty Liver Disease (MAFLD) has emerged as a significant public health concern, driven by rising global obesity rates and metabolic syndromes. This paper reviews the existing evidence on the efficacy and safety of Ursodeoxycholic Acid (UDCA) for the treatment of MAFLD, discussing the biochemical and physiological mechanisms through which UDCA may exert its effects. Furthermore, we will explore future research avenues and clinical implications.
dc.format	application/pdf
dc.identifier.uri	https://americanjournal.org/index.php/ajtas/article/view/2334
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/17144
dc.language.iso	eng
dc.publisher	American Journals Publishing
dc.relation	https://americanjournal.org/index.php/ajtas/article/view/2334/2185
dc.rights	https://creativecommons.org/licenses/by-nc/4.0
dc.source	American Journal of Technology and Applied Sciences; Vol. 28 (2024); 11-14
dc.source	2832-1766
dc.subject	MAFLD, liver, method, treatment, diagnosis.
dc.title	TREATMENT OF METABOLICALLY ASSOCIATED FATTY LIVER DISEASE IN THE YOUNG POPULATION
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: sultanovna_2024_treatment_of_metabolically_associated_fa.pdf
item.page.filesection.size: 270.88 KB
item.page.filesection.format: Adobe Portable Document Format